Cambridge Healthtech Institute’s 3rd Annual
Lead Optimization for Drug Metabolism & Safety
Tools and Strategies for Predicting, Optimizing, and Improving PKPD and Safety
April 17, 2020
Lead compounds in drug discovery need to be optimized for both efficacy and safety. Unfortunately, some of the adverse events related to drug metabolism, clearance, and drug-drug interactions (DDI) do not surface until much later in drug development. This focused one-day symposium on Lead Optimization for Drug Metabolism & Safety will bring together experts from chemistry, ADME, DMPK, and pharmacology to talk about some of the factors that must be considered early in lead optimization for addressing safety concerns that may arise later. The symposium will cover some important concepts related to drug metabolism, biotransformation, drug transport, drug-drug interactions and more, using relevant case studies and recent research findings. It will offer an opportunity for attendees to network and share ideas with experts.
LEVERAGING IN SILICO TOOLS AND MACHINE LEARNING FOR ADME PREDICTIONS
FEATURED PRESENTATION: Artificial Intelligence and Small-Molecule Drug Metabolism
S. Joshua Swamidass, MD, PhD, Assistant Professor, Immunology and Pathology, Laboratory and Genomic Medicine; Faculty Lead, Translational Informatics, Institute for Informatics, Washington University
Integration of Structure-Based and Machine Learning Approaches to Predict Inhibition of Drug Metabolizing Enzymes
Maria A. Miteva, PhD, Research Director, Molécules Thérapeutiques in silico (MTi), Inserm Institute
EARLY PREDICTION OF DOSING AND COMPOUND SAFETY
Reactive Drug Metabolite Assessment in Drug Discovery and Development
Mark Grillo, PhD, Staff Scientist, Drug Metabolism & Pharmacokinetics, MyoKardia, Inc.
Understanding the Applicability and Limitations of in silico and in vitro Safety Models towards the Design and Selection of the Safest Drug Candidates
Takafumi Takai, PhD, Senior Scientist, Discovery Toxicology, Drug Safety Research & Evaluation, Takeda, Inc.
Model-Informed Human Pharmacokinetics and Dose Prediction: Beyond IVIVC of Compound Enzyme Stability
Yurong Lai, PhD, Senior Director, Drug Metabolism, Gilead Sciences
ADME STRATEGIES FOR NEW DRUG MODALITIES
Local Metabolism Leads to Better Understanding of Tissue Drug Concentration for New Modalities
Donglu Zhang, PhD, Principal Scientist, Drug Metabolism and Pharmacokinetics, Genentech, Inc.
* The program is subject to change without notice, due to unforeseen reason.